Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Klaus Krogh
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Klaus Krogh wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study. 2018

Stemann Lau, Tobias / Dam, Gitte / Jepsen, Peter / Grønbæk, Henning / Krogh, Klaus / Gregersen, Tine. ·Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmarktobilu@rm.dk. · Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. · Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. · Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark. ·Neuroendocrinology · Pubmed #30092588.

ABSTRACT: BACKGROUND: Second primary colorectal adenocarcinomas (SPCA) may occur with a higher frequency in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In a nationwide population-based study, we investigated the risk of SPCA in GEP-NEN patients and compared it to the general population. METHODS: Using the nationwide Danish registries, we identified 2,831 GEP-NEN patients (median age 63 years [IQR 50-73 years], 53% women) diagnosed in 1995-2010. We used Cox regression to compare the incidence of SPCA in GEP-NEN patients relative to a gender- and age-matched general population sample of 56,044 persons. RESULTS: We observed 20 SPCAs among the 2,831 GEP-NEN patients with a total time at risk of 14,003 years (incidence = 143 per 100,000 person-years) and 770 colorectal adenocarcinomas in the general population of 56,044 persons with a total time at risk of 466,801 years (incidence = 165 per 100,000 person-years). The hazard ratio (HR) of SPCA from GEP-NEN diagnosis to the end of follow-up was 1.22 (95% CI: 0.78-1.92) in GEP-NEN patients compared to the general population. This nonsignificant association was the result of a strong positive association in the first 6 months after diagnosis of GEP-NEN (HR = 9.43 [95% CI: 4.98-17.86]) followed by a negative association in the remainder of the follow-up period (HR = 0.50 [95% CI: 0.20-1.21]). CONCLUSION: In this population-based study, there was no increased risk of SPCA among GEP-NEN patients. The clinical workup in newly diagnosed GEP-NEN patients likely explains the positive short-term association followed by a negative association.

2 Article [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia]. 2014

Størling, Louise / Villadsen, Gerda Elisabeth / Krogh, Klaus / Vestergaard, Peter. ·Klinisk Farmakologisk Afdeling, Bispebjerg -Hospital, Bispebjerg Bakke 23, 2400 København NV. E-mail: louisestoerling@gmail.com. ·Ugeskr Laeger · Pubmed #25292242.

ABSTRACT: This case report shows how denosumab apparently treated bisphosphonate-refractory hypercalcaemia caused by a neuroendocrine tumour of the pancreas in a 48-year-old woman. We cannot eliminate the possibility that the patient's DOTATOC-treatment contributed to the decline in plasma calcium concentration. Preliminary results from a recent large, clinical trial, suggest that denosumab is a more potent treatment of malignancy-associated hypercalcaemia than bisphosphonates.